ACM
CYTK icon

ADAR1 Capital Management’s Cytokinetics CYTK Stock Holding History

ADAR1 Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39M Sell
457,907
-174,649
-28% -$12.5M 1.79% 10
2026
Q1 		$41.7M Buy
632,556
+92,390
+17% +$5.87M 2.45% 7
2025
Q4 		$34.3M Buy
540,166
+21,245
+4% +$1.32M 2.52% 8
2025
Q3 		$28.5M Sell
518,921
-63,226
-11% -$2.6M 2.68% 11
2025
Q2 		$19.2M Buy
582,147
+191,418
+49% +$6.66M 2.95% 9
2025
Q1 		$15.7M Sell
390,729
-23,480
-6% -$1.08M 2.92% 6
2024
Q4 		$19.5M Sell
414,209
-496,973
-55% -$25.8M 3.89% 6
2024
Q3 		$48.1M Buy
911,182
+57,320
+7% +$3.19M 7.82% 1
2024
Q2 		$46.3M Buy
853,862
+534,352
+167% +$32.3M 8.73% 2
2024
Q1 		$22.4M Buy
319,510
+227,428
+247% +$17.6M 5.08% 7
2023
Q4 		$7.69M Buy
+92,082
New +$3.33M 2.75% 6

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ADAR1 Capital Management's CYTK Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Cytokinetics (CYTK) stake by 28% in Q2 2026, selling an estimated $12.5M and leaving 457,907 shares worth $39M. The position accounts for 1.79% of the portfolio, ranked #10.

ADAR1 Capital Management first reported a position in CYTK in Q4 2023 and has held it in 11 quarters since. The position peaked at $48.1M in Q3 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • ADAR1 Capital Management held 457,907 shares of Cytokinetics worth $39M as of Q2 2026.
  • ADAR1 Capital Management sold 174,649 Cytokinetics shares in Q2 2026, an estimated $12.5M.
  • Cytokinetics made up 1.79% of ADAR1 Capital Management's portfolio in Q2 2026, its #10 holding.
  • ADAR1 Capital Management first reported a position in Cytokinetics in Q4 2023 and has held it in 11 quarters since.
  • ADAR1 Capital Management's Cytokinetics position peaked at $48.1M in Q3 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.